While the current model is focused on providing quantitative insights into the behavior of lipoprotein biomarkers under anti-PCSK9 treatment in hypercholesterolemia characterized by high LDL-C levels, it remains to be seen if the same effects were to be observed in other forms of hypercholesterolemia. Here, PCSK9 is linked to Hypercholesterolemia.